HUE044115T2 - Karbidopa és L-dopa prodrogok és alkalmazásuk Parkinson-kór kezelésére - Google Patents

Karbidopa és L-dopa prodrogok és alkalmazásuk Parkinson-kór kezelésére

Info

Publication number
HUE044115T2
HUE044115T2 HUE15791424A HUE044115T2 HU E044115 T2 HUE044115 T2 HU E044115T2 HU E15791424 A HUE15791424 A HU E15791424A HU E044115 T2 HUE044115 T2 HU E044115T2
Authority
HU
Hungary
Prior art keywords
carbidopa
disease
treat parkinson
dopa prodrugs
dopa
Prior art date
Application number
Other languages
English (en)
Inventor
Benoit Cardinal-David
Vincent S Chan
Kassibla E Dempah
Brian P Enright
Rodger F Henry
Raimundo Ho
Ye Huang
Alexander D Huters
Russell C Klix
Scott W Krabbe
Philip R Kym
Yanbin Lao
Xiaochun Lou
Sean E Mackey
Mark A Matulenko
Peter T Mayer
Christopher P Miller
James Stambuli
Eric A Voight
Zhi Wang
Geoff G Zhang
Valentino J Stella
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE044115(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HUE044115T2 publication Critical patent/HUE044115T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE15791424 2014-10-21 2015-10-21 Karbidopa és L-dopa prodrogok és alkalmazásuk Parkinson-kór kezelésére HUE044115T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21

Publications (1)

Publication Number Publication Date
HUE044115T2 true HUE044115T2 (hu) 2019-10-28

Family

ID=54478240

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE15791424 HUE044115T2 (hu) 2014-10-21 2015-10-21 Karbidopa és L-dopa prodrogok és alkalmazásuk Parkinson-kór kezelésére
HUS2300009C HUS2300009I1 (hu) 2014-10-21 2023-02-20 Karbidopa és L-dopa prodrogok és alkalmazásuk Parkinson-kór kezelésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2300009C HUS2300009I1 (hu) 2014-10-21 2023-02-20 Karbidopa és L-dopa prodrogok és alkalmazásuk Parkinson-kór kezelésére

Country Status (37)

Country Link
US (7) US9446059B2 (hu)
EP (3) EP3569587A1 (hu)
JP (6) JP6567049B2 (hu)
KR (3) KR20230066484A (hu)
CN (4) CN107206013A (hu)
AR (1) AR102389A1 (hu)
AU (4) AU2015335941B2 (hu)
BR (1) BR112017008198B1 (hu)
CA (1) CA2965379A1 (hu)
CY (2) CY1121826T1 (hu)
DK (1) DK3209302T3 (hu)
ES (1) ES2739536T3 (hu)
FI (1) FIC20230014I1 (hu)
FR (1) FR23C1035I2 (hu)
HR (1) HRP20191285T1 (hu)
HU (2) HUE044115T2 (hu)
IL (3) IL251829B (hu)
LT (2) LT3209302T (hu)
LU (1) LUC00304I2 (hu)
MX (2) MX381069B (hu)
MY (1) MY189519A (hu)
NL (1) NL301224I2 (hu)
NO (1) NO2023013I1 (hu)
PH (1) PH12017500746B1 (hu)
PL (1) PL3209302T3 (hu)
PT (1) PT3209302T (hu)
RS (1) RS58972B1 (hu)
RU (2) RU2743347C2 (hu)
SA (1) SA521421115B1 (hu)
SG (1) SG11201703170RA (hu)
SI (1) SI3209302T1 (hu)
SM (1) SMT201900376T1 (hu)
TR (1) TR201908296T4 (hu)
TW (2) TWI718999B (hu)
UA (1) UA120437C2 (hu)
WO (1) WO2016065019A1 (hu)
ZA (1) ZA201702760B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
ES2967693T3 (es) 2014-03-13 2024-05-03 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
EP3445346A1 (en) * 2016-04-20 2019-02-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
WO2017223182A1 (en) * 2016-06-22 2017-12-28 Medchem Partners, Llc. Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
JP7320507B2 (ja) 2017-11-24 2023-08-03 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
EP3849533A4 (en) 2018-09-13 2022-06-22 University of Canberra PROCEDURE FOR INHIBITION
CN113015531A (zh) 2018-11-15 2021-06-22 艾伯维公司 用于皮下施用的药物调配物
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113727712B (zh) 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US20240207410A1 (en) * 2021-03-10 2024-06-27 Neuroderm, Ltd. Stabilized liquid compositions comprising a levodopa-tyrosine conjugate and uses thereof
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
DE69016688T2 (de) * 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
AU1457299A (en) * 1997-11-12 1999-05-31 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
EP1541579A1 (en) 2002-06-20 2005-06-15 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
US20050070608A1 (en) 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
EP1677759A1 (en) 2003-10-31 2006-07-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
RU2365580C2 (ru) 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
CN101023090B (zh) 2004-07-06 2013-03-27 雅培制药有限公司 Hiv蛋白酶抑制剂的前药
TWI403493B (zh) * 2005-12-05 2013-08-01 Xenoport Inc 左旋多巴前藥的甲磺酸鹽，其組成物，及其用途
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
KR20090033871A (ko) * 2006-06-16 2009-04-06 솔베이 파마슈티칼스 비. 브이 비페프루녹스 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
ATE510537T1 (de) * 2008-02-06 2011-06-15 Wockhardt Research Center Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit
KR101698028B1 (ko) 2008-05-20 2017-01-26 노이로제스엑스, 인코포레이티드 수용성 아세트아미노펜 유사체
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
WO2010134074A1 (en) 2009-05-19 2010-11-25 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8937151B2 (en) 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
EP2640358B1 (en) 2010-11-15 2018-01-03 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
EP2647619B1 (en) 2010-12-02 2015-01-21 Ono Pharmaceutical Co., Ltd. Novel compound and medical use thereof
BR112013014304A2 (pt) 2010-12-10 2016-07-19 Synagile Corp composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
WO2012158527A2 (en) * 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
PT2968218T (pt) 2013-03-13 2021-09-24 Neuroderm Ltd Combinação para tratamento da doença de parkinson
CA3212170A1 (en) 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
EP3445346A1 (en) 2016-04-20 2019-02-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
WO2018059739A1 (en) 2016-09-29 2018-04-05 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
US20230106081A1 (en) 2023-04-06
CA2965379A1 (en) 2016-04-28
FR23C1035I2 (fr) 2025-04-18
AU2023210650A1 (en) 2023-08-24
JP6750076B2 (ja) 2020-09-02
UA120437C2 (uk) 2019-12-10
RU2017117413A3 (hu) 2019-05-30
TWI718999B (zh) 2021-02-21
CN111454290A (zh) 2020-07-28
AR102389A1 (es) 2017-02-22
CN107206013A (zh) 2017-09-26
KR20240113982A (ko) 2024-07-23
CY2023010I2 (el) 2023-06-09
MX381069B (es) 2025-03-12
FIC20230014I1 (fi) 2023-03-31
TW202131931A (zh) 2021-09-01
BR112017008198B1 (pt) 2021-02-09
US20180079762A1 (en) 2018-03-22
KR102537018B1 (ko) 2023-05-30
NL301224I2 (nl) 2023-08-16
US20160106765A1 (en) 2016-04-21
LT3209302T (lt) 2019-06-10
PH12017500746B1 (en) 2021-12-15
HUS2300009I1 (hu) 2023-03-28
PH12017500746A1 (en) 2017-10-30
JP6932227B2 (ja) 2021-09-08
CY2023010I1 (el) 2023-06-09
IL268885A (en) 2019-10-31
NL301224I1 (hu) 2023-03-29
WO2016065019A1 (en) 2016-04-28
MX2017005236A (es) 2017-07-26
IL251829A0 (en) 2017-06-29
RU2743347C2 (ru) 2021-02-17
PL3209302T3 (pl) 2019-10-31
HRP20191285T1 (hr) 2019-10-18
TW201630924A (zh) 2016-09-01
US20160362431A1 (en) 2016-12-15
EP3569587A1 (en) 2019-11-20
DK3209302T3 (da) 2019-05-13
US10730895B2 (en) 2020-08-04
AU2021201414A1 (en) 2021-03-25
RU2017117413A (ru) 2018-11-26
CN111362980A (zh) 2020-07-03
IL251829B (en) 2019-09-26
EP3209302B1 (en) 2019-04-24
NO2023013I1 (no) 2023-03-20
AU2015335941B2 (en) 2021-04-01
US20190375770A1 (en) 2019-12-12
CN111362980B (zh) 2022-10-18
JP2019218356A (ja) 2019-12-26
IL268885B (en) 2020-08-31
AU2021201414B2 (en) 2023-05-11
CN111494395B (zh) 2024-06-21
MX2021003840A (es) 2022-06-30
AU2025238004A1 (en) 2025-10-16
SI3209302T1 (sl) 2019-06-28
RS58972B1 (sr) 2019-08-30
IL276493A (en) 2020-09-30
CY1121826T1 (el) 2020-07-31
JP2025118978A (ja) 2025-08-13
LTC3209302I2 (hu) 2025-10-10
JP2021183628A (ja) 2021-12-02
PT3209302T (pt) 2019-07-19
US11091507B2 (en) 2021-08-17
JP2017537066A (ja) 2017-12-14
NZ769153A (en) 2024-04-26
ZA201702760B (en) 2022-05-25
JP6567049B2 (ja) 2019-08-28
US20220153765A1 (en) 2022-05-19
US20200262852A1 (en) 2020-08-20
ES2739536T3 (es) 2020-01-31
JP7688087B2 (ja) 2025-06-03
LUC00304I2 (hu) 2025-09-22
CN111494395A (zh) 2020-08-07
RU2021103000A (ru) 2021-03-01
MX393568B (es) 2025-03-24
JP2020189864A (ja) 2020-11-26
JP2023174770A (ja) 2023-12-08
US9446059B2 (en) 2016-09-20
AU2015335941A1 (en) 2017-05-04
FR23C1035I1 (fr) 2023-12-08
TR201908296T4 (tr) 2019-06-21
BR112017008198A2 (pt) 2017-12-26
LTPA2023519I1 (hu) 2023-06-26
SMT201900376T1 (it) 2019-09-09
TWI755257B (zh) 2022-02-11
KR20170071599A (ko) 2017-06-23
CN111454290B (zh) 2022-12-23
MY189519A (en) 2022-02-16
EP3209302A1 (en) 2017-08-30
SG11201703170RA (en) 2017-05-30
NZ730996A (en) 2024-04-26
KR20230066484A (ko) 2023-05-15
SA521421115B1 (ar) 2022-03-01
US10174061B2 (en) 2019-01-08
EP4186510A1 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
IL276493A (en) Carbidopa and L-dopa prodrugs and methods for use in the treatment of Parkinson's disease
IL280530A (en) Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease
IL274648A (en) Promote new catecholamine drugs for use in the treatment of Parkinson's disease
IL251530A0 (en) Use of cannabinoids in the treatment of skeletal muscle atrophy
ZA201606158B (en) Treatment of metabolic disorders in equine animals
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
PL3096765T3 (pl) Leczenie zaburzeń metabolicznych u zwierząt psowatych
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
SI3722291T1 (sl) Indolinonske spojine in njihova uporaba pri zdravljenju fibrotičnih bolezni
IL274203A (en) A pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
GB201504144D0 (en) Treatment of Parkinson's disease
PT3485890T (pt) Inibidores de sglt2 para o tratamento de distúrbios metabólicos em animais caninos
PT3721882T (pt) Tratamento de disfunção da pars intermédia da pituitária em animais equinos